Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
M MUSCULO-SKELETAL SYSTEM
M04 ANTIGOUT PREPARATIONS
M04A ANTIGOUT PREPARATIONS
M04AB Preparations increasing uric acid excretion
M04AB05 Lesinurad
D09921 Lesinurad (USAN/INN)
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG02042 Uricosurics
DG01388 Lesinurad
D09921 Lesinurad
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01388 Lesinurad
D09921 Lesinurad
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC22
OAT4
D09921 Lesinurad (USAN/INN)
URAT1
D09921 Lesinurad (USAN/INN)
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09921
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09921
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09921
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09921
Pharmacogenomic biomarkers [br08341.html]
Polymorphisms and mutations affecting drug response
D09921
Drug groups [BR:br08330]
Musculo-skeletal system agent
DG02042 Uricosurics
DG01388 Lesinurad
Metabolizing enzyme substrate
DG01642 CYP2C9 substrate
DG01388 Lesinurad